ClinicalTrials.gg
RecruitingNCT06015971Updated May 6, 2025

Omega-3 Fatty Acids and Nutritional Support in Gastrointestinal Cancer

An interventional study of omega-3 and Standard in Sarcopenia, sponsored by Maimónides Biomedical Research Institute of Córdoba. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-06.

Sponsored by Maimónides Biomedical Research Institute of Córdoba · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 99 studies in Sarcopenia with a site in Spain — 33 open to participants now, 40 under way, none of them phase 3. Sarcopenia · Spain.

Planned enrollment
60th of 77
40 · median 72
Started
2023
with 5 others
No phase
70 of 99
26 open now
Primary completion
2026-12
later than 20 of 39 live
Registered
54th of 99
by date
Lead sponsor
4 of 99
Maimónides Biomedical Research Institute of Córdoba

Among the 99 studies in Sarcopenia with a site in Spain, this one is the 60th largest by planned enrollment of the 77 interventional ones that give a count, is one of 6 that started in 2023, is one of 70 with no phase, reaches primary completion later than 20 of the 39 other live ones, and was the 54th registered.

Sarcopenia

1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

33 of the 99 studies in Sarcopenia with a site in Spain are open now. Recruiting first, the newest first:

27 more — sign in →

All 33 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Sarcopenia with a site in Spain, or all of them as a file.
02

Study summary

Sarcopenia is a frequent complication in patients with cancer and chronic diseases, it is characterized by decreased muscle strength and fatigue due to reduced skeletal muscle mass, which is accompanied by atrophy and decreased quality of muscle tissue. In all cases, it negatively impacts treatment tolerance, clinical outcomes and survival, in consequence, quality of life of these patients decreases while morbidity, mortality and costs increase. In this context, appropriate nutritional screening and early nutrition support are extremely recommended, to this aim, in some cases, oral nutritional supplements (ONS) are necessary; ONS could have a standard formula or be enriched with specific nutrients (arginine, glutamine, branched chain amino acids, n-3 fatty acids, and nucleotides), which can modulate the activity of the immune system and provide an additional benefit beyond the nutritional support, this intervention type is called immunonutrition. Despite these possible benefits, their utility has been proven in few clinical scenarios, for example in with patients with upper gastrointestinal cancer undergoing surgical resection; based on this, current guidelines recommend that patients should receive oral/enteral nutritional support with an specific formula enriched in immunonutrients (with arginine, n-3 fatty acids or nucleotides) , but there is a lack of evidence for supporting its use in other clinical conditions including patients with cancer that receive systemic treatment

03

Conditions studied

  • Sarcopenia

Keywords

  • cancer
  • nutritional support
  • omega-3 enriched nutritional supplements
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Patients with Gastrointestinal tumor undergoing systemic treatment (chemo-radio-immuno therapy or their combination)
  • Body weight loss >5% in the previous three months or >10% in the previous six months
  • Both sexes
  • Age between 18-85 y-old.

Exclusion criteria

Exclusion Criteria:

  • \< 2 weeks
  • \< 15 mL/min
  • End-stage liver disease
  • Any musculoskeletal, cardiovascular and/or neurological disorders that could affect exercising.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    standard hypercaloric, hyperproteic oral supplement

    Dietary Supplement: Standard

  • Experimental
    omega-3 enriched oral supplement

    Dietary Supplement: omega-3

Interventions

  • Dietary supplementOmega-3 fatty acidStudies of Omega-3 fatty acidOmega-3 fatty acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Take 2 omega-3 enriched oral supplements per day plus physical activity and Mediterranean Diet

  • Dietary supplementStandard

    Take 2 hypercaloric hyperproteic oral supplements per day plus physical activity and Mediterranean Diet

06

What researchers measure

Primary outcomes

  1. Muscle mass

    Muscle mass change (in Kg)

    Time frame: 12 weeks

  2. Functionality

    Changes in functionality measured with the Up and Go Test

    Time frame: 12 weeks

Secondary outcomes

  1. Albumin

    Changes in serum albumin levels (g/dl)

    Time frame: 12 weeks

  2. C-RP

    Changes in serum C-RP(g/dl)

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Dec 2026, 41 months after the start.

Of 497 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 41 months is above that.

Counting every sponsor, half of 509 studies reached it within 18 months; a quarter within 8 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2023
First posted
Aug 29, 2023
StartActual
Jul 1, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
May 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06015971
Lead sponsor
Maimónides Biomedical Research Institute of Córdoba
Responsible party
Sponsor
First posted
Aug 29, 2023
Start date
Jul 1, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 6, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omega-3 fatty acid

Start the discussion